(Ordesekimab)Biosimilar Reference Antibody-GS40512

货号：GS40512

Ordesekimab (brand name Oscikimab, formerly AMG‑714 or PRV‑015) is a humanized IgG1‑kappa monoclonal antibody that specifically targets interleukin‑15 (IL‑15), a cytokine critical for the activation, proliferation, and survival of T cells and natural killer (NK) cells. As an IgG1 isotype, it is designed to engage immune effector functions such as antibody‑dependent cellular cytotoxicity (ADCC). By binding to IL‑15, it neutralizes the cytokine and prevents it from signaling through its receptor complex (IL‑15Rα/IL‑2Rβγc), thereby modulating immune responses. It is being developed as an immunomodulatory therapy for autoimmune and inflammatory diseases, with clinical studies focusing on celiac disease, rheumatoid arthritis, and other IL‑15‑driven disorders.